Abstract:Polycomb Repressive Complex 2 (PRC2) is a multi-protein complex with important roles in development and cancer. Both hyper- and hypoactivity of PRC2 are associated with blood-related malignancies. Activating mutations of the PRC2 methyltransferase EZH2 have been found in human B-lineage lymphomas. Inactivating mutations of PRC2 components EZH2 , EED and SUZ12 have been described in early T-cell Precursor ALL (ETP-ALL) and inactivating PRC2-alterations are found in Myelodysplastic and Myeloproliferative Syndromes. The mechanisms underlying this paradox are incompletely understood. We here investigate the context dependent role of PRC2 in murine models. We initially studied PRC2 in normal hematopoiesis: Chip-seq analysis of the PRC2-mediated H3K27me3 chromatin mark demonstrates that many genes highly expressed in immature hematopoiesis gain H3K27me3 in the developmental transition from more immature Lin-Sca1+Kit+ (LSK) cells to lineage committed Granulocyte Macrophage Progenitors (GMPs). Transcription of these genes is enriched in EZH2 ko GMP compared to EZH2 ff GMP by Gene Set Enrichment Analysis (GSEA). These data suggest that PRC2 is important for the silencing of immature gene expression programs in the developmental transition from LSK to GMP. We next analyzed the role of PRC2 in two murine models of acute leukemia: MLL-AF9 driven leukemia, and a model of early T-cell precursor T-ALL (ETP-ALL). In MLL-AF9 leukemia, we previously found that inactivation of Eed completely abrogate leukemogenesis in vitro and in vivo. We now report that genetic inactivation of the tumor suppressor Cdkn2a (a canonical PRC2 target) partially rescued MLL-AF9 mediated leukemia in vitro and in vivo. However, Cdkn2a ko EED ko MLL-AF9 leukemia remained compromised. In vitro growth was reduced to approximately 10% of Eed ff controls. While control MLL-AF9 leukemia developed in vivo in 100% of the recipients, Cdkn2a ko EED ko MLL-AF9 leukemia developed with significantly prolonged latency and incomplete penetrance (25%). RNAseq analysis revealed that high level expression of genes with established roles in MLL-AF9 leukemia such as HoxA9, Cdk6 and Jmjd1c unexpectedly depends on Eed. These data are in keeping with the absence of alterations in PRC2-components in human MLL-rearranged leukemia. In contrast, PRC2 core components ( EZH2/EED/SUZ12 ) are deleted or mutated in > 40% of ETP-ALL. ETP-ALL also often has direct or indirect activation of the RAS-pathway, and carries frequent deletions of the CDKN2A locus. To model the effects of EED and EZH2- inactivation in ETP-ALL, we established Cdkn2a ko Eed ff vs Cdkn2a ko Eed ko , and Cdkn2a ko Ezh2 ff vs Cdkn2a ko EZH2 ko leukemias by transduction with NRASQ61K followed by expansion on OP9DL1 stroma cells to activate T-lineage differentiation via Notch-signaling. Cdkn2a ko NRASQ61K leukemia showed an immunophenotype similar to human ETP-ALL (positive for c-Kit, CD5 and myeloid markers and mostly negative for CD4/8). Inactivation of Eed or Ezh2 in this model led to a shortening of latency (p=0.03 for Eed , p=0.0001 for Ezh2 ). RNAseq revealed enrichment of genes associated with murine DN1 thymocytes and with human ETP-ALL in Eed ko vs Eed ff Cdkn2a ko NRASQ61K leukemia. These genesets showed even more pronounced enrichment in Ezh2 ko compared to Ezh2 ff Cdkn2a ko NRASQ61K leukemia. Genes highly expressed in early hematopoiesis were enriched in Eed ko and Ezh2 ko cells in both, the MLL-AF9 and NRASQ61K leukemia models. However, there was an opposing effect on HoxA9 gene expression, with PRC2 inactivation leading to decreased HoxA9 expression in MLL-AF9 , and increased HoxA9 expression in Cdkn2a ko NRASQ61K leukemia. D ecreased HoxA9 has been shown to impair MLL-AF9 leukemia growth. To test the functional significance of elevated HoxA9 -levels in the Eed ko and EZH2 ko NRASQ61K leukemias, we co-expressed HoxA9 and NRASQ61K in the presence of intact Eed and Ezh2 loci. Preliminary data suggest that HoxA9 accelerates leukemia development in this setting. Alterations in chromatin modifiers, including PRC2, are frequent in leukemia and lymphoma. Our data demonstrate that manipulation of PRC2 can have opposite effects on leukemia phenotype and expression of key PRC2-repressed genes such as HoxA9 in the context of different tumors. We are currently characterizing the mechanisms leading to divergent outcomes of PRC2 manipulation in MLL-AF9 leukemia compared to NRASQ61K ETP-like leukemia. Disclosures Armstrong: Epizyme : Consultancy.

Polycomb Repressive Complex 2 is Required for MLL-AF9 Leukemia

Context Dependent Role of Polycomb Repressive Complex 2 in Acute Leukemia

Inactivation of Eed impedes MLL-AF9–mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia

Chronic Myelogenous Leukemia – Initiating Cells Require Polycomb Group Protein EZH 2

Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a

Eradication of Chronic Myelogenous Leukemia by Inactivation of the Polycomb Group Protein Ezh2

Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner.

Loss of MBD2 Attenuates MLL-AF9-driven Leukemogenesis by Suppressing the Leukemic Cell Cycle Via CDKN1C

Ezh2 Loss Propagates Hypermethylation at T Cell Differentiation–regulating Genes to Promote Leukemic Transformation

The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia

A methylation-phosphorylation switch controls EZH2 stability and hematopoiesis

NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation

Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement

FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia

Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia

PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia.

Dnmt3a is Required For Aberrant Self-Renewal Driven by PML-RARA